Related references
Note: Only part of the references are listed.Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial
Juan C. Arjona Ferreira et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2013)
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
Samuel S. Engel et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
Alexandra E. Butler et al.
DIABETES (2013)
Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
Juan Camilo Arjona Ferreira et al.
DIABETES CARE (2013)
Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?
M. Burgmaier et al.
DIABETIC MEDICINE (2013)
Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis
Andre Scheen
EXPERT OPINION ON DRUG SAFETY (2013)
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety
Carolyn F. Deacon et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes
Vivian Fonseca et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes
Andre J. Scheen
POSTGRADUATE MEDICINE (2013)
COST-EFFECTIVENESS ANALYSIS OF USING HYPOGLYCEMIC AGENTS (LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN, GLIMEPIRIDE AND GLIBENCLAMIDE) WITH METFORMIN IN DIABETES IN COLOMBIA
M. Romero et al.
VALUE IN HEALTH (2013)
HEALTH CARE RESOURCE USE AND COSTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AFTER TREATMENT INITIATION WITH SAXAGLIPTIN OR SITAGLIPTIN
A. Kaltenboeck et al.
VALUE IN HEALTH (2013)
Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52weeks
Takashi Kadowaki et al.
JOURNAL OF DIABETES INVESTIGATION (2013)
Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study
D. T. Eurich et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes
Adrian S. Dobs et al.
JOURNAL OF DIABETES (2013)
Glucagon-like Peptide 1-Based Drugs and Pancreatic Safety
Kimberly G. Brodovicz et al.
JAMA INTERNAL MEDICINE (2013)
Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus A Population-Based Matched Case-Control Study
Sonal Singh et al.
JAMA INTERNAL MEDICINE (2013)
Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
Samuel S. Engel et al.
DIABETES THERAPY (2013)
Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
Larry K. Golightly et al.
CLINICAL PHARMACOKINETICS (2012)
The L-α-Lysophosphatidylinositol/GPR55 System and Its Potential Role in Human Obesity
Jose Maria Moreno-Navarrete et al.
DIABETES (2012)
Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) A 26-week double-blind study
David Russell-Jones et al.
DIABETES CARE (2012)
Diagnosis and Classification of Diabetes Mellitus
DIABETES CARE (2012)
Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes
Richard E. Pratley et al.
DIABETES CARE (2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes
J. Wainstein et al.
DIABETES OBESITY & METABOLISM (2012)
Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis
M. Pendergrass et al.
DIABETES OBESITY & METABOLISM (2012)
Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis
P. S. George et al.
DIABETIC MEDICINE (2012)
Dapagliflozin A Review of its Use in Type 2 Diabetes Mellitus
Greg L. Plosker
DRUGS (2012)
Linagliptin A Review of its Use in the Management of Type 2 Diabetes Mellitus
Emma D. Deeks
DRUGS (2012)
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial
Pablo Aschner et al.
LANCET (2012)
Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
Akira Kubota et al.
JOURNAL OF DIABETES INVESTIGATION (2012)
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes*
Wenying Yang et al.
JOURNAL OF DIABETES (2012)
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males
Gary A. Herman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
Nir Barzilai et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
Matteo Monami et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Weight-Related Quality of Life, Health Utility, Psychological Well-Being, and Satisfaction With Exenatide Once Weekly Compared With Sitagliptin or Pioglitazone After 26 Weeks of Treatment
Jennie H. Best et al.
DIABETES CARE (2011)
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial
R. Arechavaleta et al.
DIABETES OBESITY & METABOLISM (2011)
A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents
L. Olansky et al.
DIABETES OBESITY & METABOLISM (2011)
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus
C. Reasner et al.
DIABETES OBESITY & METABOLISM (2011)
Sitagliptin/Metformin Fixed-Dose Cambination In Patients with Type 2 Diabetes Mellitus
Claudine M. Chwieduk
DRUGS (2011)
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies
Michael Elashoff et al.
GASTROENTEROLOGY (2011)
Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus
Yasuji Arase et al.
HEPATOLOGY RESEARCH (2011)
Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes
A. Perez-Monteverde et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
R. Pratley et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes
K. H. Yoon et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Does Not Affect the Pharmacokinetics of Ethinyl Estradiol or Norethindrone in Healthy Female Subjects
Elizabeth Migoya et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Management of type 2 diabetes: new and future developments in treatment
Abd A. Tahrani et al.
LANCET (2011)
COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO SITAGLIPTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
A. Hutchings et al.
VALUE IN HEALTH (2011)
Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes
Atsunori Kashiwagi et al.
JOURNAL OF DIABETES INVESTIGATION (2011)
Long-term safety, tolerability, and efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes
Masato Odawara et al.
DIABETOLOGY INTERNATIONAL (2011)
Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control
Naoko Tajima et al.
DIABETOLOGY INTERNATIONAL (2011)
Bioequivalence of Sitagliptin/Metformin Fixed-Dose Combination Tablets and Concomitant Administration of Sitagliptin and Metformin in Healthy Adult Subjects A Randomized, Open-Label, Crossover Study
Elizabeth M. Migoya et al.
CLINICAL DRUG INVESTIGATION (2010)
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Rajesh Garg et al.
DIABETES CARE (2010)
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
D. Williams-Herman et al.
DIABETES OBESITY & METABOLISM (2010)
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
P. Aschner et al.
DIABETES OBESITY & METABOLISM (2010)
Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial
Y. Iwamoto et al.
DIABETES OBESITY & METABOLISM (2010)
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
T. Vilsboll et al.
DIABETES OBESITY & METABOLISM (2010)
Mortality attributable to diabetes: Estimates for the year 2010
Gojka Roglic et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
Global estimates of the prevalence of diabetes for 2010 and 2030
J. E. Shaw et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
Andre J. Scheen et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2010)
Sitagliptin A Review of its Use in the Management of Type 2 Diabetes Mellitus
Sohita Dhillon
DRUGS (2010)
Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus
Yasuhiko Iwamoto et al.
ENDOCRINE JOURNAL (2010)
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
T. Seck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
S. S. Engel et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Richard M. Bergenstal et al.
LANCET (2010)
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Richard E. Pratley et al.
LANCET (2010)
LONG-TERM COST-CONSEQUENCE ANALYSIS OF EXENATIDE ONCE WEEKLY VERSUS SITAGLIPTIN OR PIOGLITAZONE IN TYPE 2 DIABETES PATIENTS IN THE UNITED STATES
Gaebler J. Aledort et al.
VALUE IN HEALTH (2010)
ADDITION OF INCRETIN-THERAPY TO METFORMIN IN TYPE-2-DIABETES MELLITUS (T2DM): COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS SITAGLIPTIN FROM THE PERSPECTIVE OF THE GERMAN STATUTORY HEALTH INSURANCE (SHI)
M. Schlander et al.
VALUE IN HEALTH (2010)
Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy
Maureen J. Lage et al.
ADVANCES IN THERAPY (2009)
Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk
A. L. PETERS
CLEVELAND CLINIC JOURNAL OF MEDICINE (2009)
New treatments in type 2 diabetes: a focus on the incretin-based therapies
Anthony H. Barnett
CLINICAL ENDOCRINOLOGY (2009)
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study
Debora Williams-Herman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
David D. Dore et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea
Viswanathan Mohan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects
Daniel M. Bloomfield et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects
Goutam C. Mistry et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
New drugs for the treatment of diabetes - Part II: Incretin-based therapy and beyond
Silvio E. Inzucchi et al.
CIRCULATION (2008)
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
Itamar Raz et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy
B. Schwarz et al.
DIABETES OBESITY & METABOLISM (2008)
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes
R. Scott et al.
DIABETES OBESITY & METABOLISM (2008)
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
J. C. N. Chan et al.
DIABETES OBESITY & METABOLISM (2008)
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes
Kenji Nonaka et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers
Arthur Bergman et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
K. Hermansen et al.
DIABETES OBESITY & METABOLISM (2007)
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers
Arthur Bergman et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2007)
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
Barry J. Goldstein et al.
DIABETES CARE (2007)
Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor
Arthur J. Bergman et al.
DIABETES CARE (2007)
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
Markolf Hanefeld et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Dipeptidyl peptidase-4 inhibitors -: Clinical data and clinical implications
Bo Ahren
DIABETES CARE (2007)
Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans
Stella H. Vincent et al.
DRUG METABOLISM AND DISPOSITION (2007)
Rationale for dipeptidyl peptidase 4 inhibitors: A new class of oral agents for the treatment of type 2 diabetes mellitus
R. Keith Campbell
ANNALS OF PHARMACOTHERAPY (2007)
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes
R. Scott et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
M. A. Nauck et al.
DIABETES OBESITY & METABOLISM (2007)
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Pablo Aschner et al.
DIABETES CARE (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
Bernard Charbonnel et al.
DIABETES CARE (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
I. Raz et al.
DIABETOLOGIA (2006)
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
Gary A. Herman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Julio Rosenstock et al.
CLINICAL THERAPEUTICS (2006)
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects
Gary A. Herman et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers
AJ Bergman et al.
CLINICAL THERAPEUTICS (2006)
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
GA Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
D Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Share Paper
